Title:
CHOROIDAL NEOVASCULARIZATION SUPPRESSOR OR DRUSEN FORMATION SUPPRESSOR, AND METHOD FOR ASSESSING OR SCREENING FOR SAME
Document Type and Number:
WIPO Patent Application WO/2017/104833
Kind Code:
A1
Abstract:
The existing therapeutic agents for CNV are only medicines for symptomatic therapies, and therefore a radical therapeutic agent for CNV has been keenly demanded. There is no therapeutic agent for Dry AMD, and therefore a radical therapeutic agent for Dry AMD has been keenly demanded.
The present invention provides a prophylactic and/or therapeutic agent for choroidal neovascularization, which contains a compound having an activity of suppressing the epithelial mesenchymal transition of a retinal pigment epithelial cell as an active ingredient. The present invention also provides a drusen formation suppressor, which contains a compound having an activity of suppressing the epithelial mesenchymal transition of a retinal pigment epithelial cell as an active ingredient.
Inventors:
NIWA SHINICHIRO (JP)
OGURA DAI (JP)
MIZUNUMA HIDEMI (JP)
ARAI YOKO (JP)
KUROSE TAKAHIRO (JP)
TAKAI YOSHIHIRO (JP)
MITSUGUCHI YOKO (JP)
MORIYA MARIYO (JP)
OGURA DAI (JP)
MIZUNUMA HIDEMI (JP)
ARAI YOKO (JP)
KUROSE TAKAHIRO (JP)
TAKAI YOSHIHIRO (JP)
MITSUGUCHI YOKO (JP)
MORIYA MARIYO (JP)
Application Number:
PCT/JP2016/087647
Publication Date:
June 22, 2017
Filing Date:
December 16, 2016
Export Citation:
Assignee:
LINK GENOMICS INC (JP)
ROHTO PHARMA (JP)
ROHTO PHARMA (JP)
International Classes:
A61K31/421; A61K31/192; A61K31/38; A61K31/404; A61K31/41; A61K31/426; A61K31/436; A61K31/47; A61K45/00; A61P27/02; A61P43/00
Other References:
HIRASAWA M ET AL.: "Transcriptional factors associated with epithelial-mesenchymal transition in choroidal neovascularization", MOLECULAR VISION, vol. 17, 6 May 2011 (2011-05-06), pages 1222 - 1230, XP055393487, Retrieved from the Internet >
ZHOU X ET AL.: "Sulindac has strong antifibrotic effects by suppressing STAT3- related miR-21", J. CELL .MOL.MED., vol. 19, no. 5, May 2015 (2015-05-01), pages 1103 - 1113, XP055393488
HWANG KE ET AL.: "Down-regulated SIRT1 by Nonsteroidal Antiinflammatory Drugs is to Inhibit TGF-1 induced Epithelial-Mesenchymal Transition and to Suppress Migration and Invasion in Lung Cancer", CHEST, vol. 148, no. 4, October 2015 (2015-10-01), XP055393502
SUR A ET AL.: "Pharmacological protection of retinal pigmented epithelial cells by sulindac involves PPAR-alpha", PROC NATL ACAD SCI USA, vol. 111, no. 47, 2014, pages 16754 - 16759, XP055393506
SAKAMOTO T ET AL.: "Non-steroidal anti- inflammatory drug(NSAID) in exudative AMD", JOURNAL OF JAPANESE OPHTHALMOLOGICAL SOCIETY, vol. 114, 2010, pages 127, XP009507131
SUZUKI M ET AL.: "Cyclooxygenase inhibitor improved an exudative lesion of choroidal neovascularization in age-related macular degeneration", EUROPEAN JOURNAL OF OPHTHALMOLOGY, vol. 22, no. 3, 2012, pages 495 - 498, XP009507126
TAKAHASHI E ET AL.: "Tumor Necrosis Factor-alpha Regulates Transforming Growth Factor-beta- dependent Epithelial-Mesenchyamal Transition by Promoting Hyaluronan- CD 44-Moesin Interaction", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 285, no. 6, 5 February 2010 (2010-02-05), pages 4060 - 4073, XP055331701, Retrieved from the Internet
ERI TAKAHASHI: "The Regulation of Epithelial Mesenchymal Transition in Ocular Disorders", JOURNAL OF JAPANESE OPHTHALMOLOGICAL SOCIETY, vol. 120, no. 11, November 2016 (2016-11-01), pages 783 - 790, XP009507132
See also references of EP 3391883A4
ZHOU X ET AL.: "Sulindac has strong antifibrotic effects by suppressing STAT3- related miR-21", J. CELL .MOL.MED., vol. 19, no. 5, May 2015 (2015-05-01), pages 1103 - 1113, XP055393488
HWANG KE ET AL.: "Down-regulated SIRT1 by Nonsteroidal Antiinflammatory Drugs is to Inhibit TGF-1 induced Epithelial-Mesenchymal Transition and to Suppress Migration and Invasion in Lung Cancer", CHEST, vol. 148, no. 4, October 2015 (2015-10-01), XP055393502
SUR A ET AL.: "Pharmacological protection of retinal pigmented epithelial cells by sulindac involves PPAR-alpha", PROC NATL ACAD SCI USA, vol. 111, no. 47, 2014, pages 16754 - 16759, XP055393506
SAKAMOTO T ET AL.: "Non-steroidal anti- inflammatory drug(NSAID) in exudative AMD", JOURNAL OF JAPANESE OPHTHALMOLOGICAL SOCIETY, vol. 114, 2010, pages 127, XP009507131
SUZUKI M ET AL.: "Cyclooxygenase inhibitor improved an exudative lesion of choroidal neovascularization in age-related macular degeneration", EUROPEAN JOURNAL OF OPHTHALMOLOGY, vol. 22, no. 3, 2012, pages 495 - 498, XP009507126
TAKAHASHI E ET AL.: "Tumor Necrosis Factor-alpha Regulates Transforming Growth Factor-beta- dependent Epithelial-Mesenchyamal Transition by Promoting Hyaluronan- CD 44-Moesin Interaction", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 285, no. 6, 5 February 2010 (2010-02-05), pages 4060 - 4073, XP055331701, Retrieved from the Internet
ERI TAKAHASHI: "The Regulation of Epithelial Mesenchymal Transition in Ocular Disorders", JOURNAL OF JAPANESE OPHTHALMOLOGICAL SOCIETY, vol. 120, no. 11, November 2016 (2016-11-01), pages 783 - 790, XP009507132
See also references of EP 3391883A4
Attorney, Agent or Firm:
UNIUS PATENT ATTORNEYS OFFICE (JP)
Download PDF:
Previous Patent: IDLE STOP CONTROL DEVICE AND FAULT DIAGNOSIS SYSTEM
Next Patent: METHOD FOR FORMING ANTIREFLECTION OPTICAL BODY, AND DISPLAY PANEL
Next Patent: METHOD FOR FORMING ANTIREFLECTION OPTICAL BODY, AND DISPLAY PANEL